Met in lung cancer

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 653-654

  Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

ALK; c Met; Combination therapy; EGFR; mTOR; Targeted cancer therapy

Indexed keywords

AFATINIB; CM 118; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; RAPAMYCIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CM-118; PROTEIN TYROSINE KINASE; PYRIDAZINE DERIVATIVE; PYRIDONE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG POTENCY; HUMAN; LUNG NON SMALL CELL CANCER; NOTE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; ANIMAL; GLIOMA; METABOLISM; STOMACH NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; GLIOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDAZINES; PYRIDONES; RECEPTOR PROTEIN-TYROSINE KINASES; STOMACH NEOPLASMS;

EID: 84901699077     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28504     Document Type: Note

References (11)

1. Sharma SV, Settleman J. ErbBs in lung cancer. Exp Cell Res 2009; 315:557-71; PMID:18721806; http://dx.doi.org/10.1016/j.yexcr.2008.07.026
2. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 2005; 70:419-26; PMID:16869779; http://dx.doi.org/10.1101/sqb.2005.70.043
3. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37:1315-6; PMID:16258541; http://dx.doi.org/ 10.1038/ng1671
4. Bowles DW, Weickhardt A, Jimeno A. Afatinib for the treatment of patients with EGFR-positive nonsmall cell lung cancer. Drugs Today (Barc) 2013; 49:523-35; PMID:24086949
5. Cadranel J, Ruppert AM, Beau-Faller M, Wislez M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Crit Rev Oncol Hematol 2013; 88:477-93; PMID:23911281; http://dx.doi.org/10.1016/j.critrevonc.2013.06. 009
6. Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang JM, et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 2014; 15:570-7; PMID:24556908; http://dx.doi.org/10.4161/cbt.28162
7. Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2014; 89:284-99; PMID:24355409; http://dx.doi.org/10.1016/j.critrevonc.2013.11.006
8. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12:89-103; PMID:22270953; http://dx.doi.org/10.1038/nrc3205
9. Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K. A novel lead compound CM-118: Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. Cancer Biol Ther 2014; 15:721-34; PMID:24618813; http://dx.doi.org/10. 4161/cbt.28409
10. Keating GM. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 2014; 74:207-21; PMID:24435321; http://dx.doi.org/10.1007/s40265-013-0170-8
11. A Study Of Combined C-MET Inhibitor And PANHER Inhibitor (PF-02341066 and PF-00299804) In Patients With Non-Small Cell Lung Cancer. Pfizer; 2010 May 10 [updated 2014 Mar 6; cited 2014 Mar 10]. Available from: http://www. clinicaltrials.gov/show/NCT01121575